Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes

ClinicalTrials.gov ID: NCT01850615

Public ClinicalTrials.gov record NCT01850615. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 1:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT01850615
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
323 participants

Conditions and interventions

Interventions

  • Faster-acting insulin aspart Drug
  • basal insulin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 22, 2013
Primary completion
Nov 16, 2014
Completion
Nov 16, 2014
Last update posted
Jun 11, 2019

2013 – 2014

United States locations

U.S. sites
32
U.S. states
22
U.S. cities
30
Facility City State ZIP Site status
Novo Nordisk Investigational Site Birmingham Alabama 35211
Novo Nordisk Investigational Site Birmingham Alabama 35216
Novo Nordisk Investigational Site Peoria Arizona 85381
Novo Nordisk Investigational Site Little Rock Arkansas 72205
Novo Nordisk Investigational Site Santa Ana California 92705
Novo Nordisk Investigational Site Tarzana California 91356-3551
Novo Nordisk Investigational Site Colorado Springs Colorado 80907
Novo Nordisk Investigational Site Colorado Springs Colorado 80922
Novo Nordisk Investigational Site Clearwater Florida 33765
Novo Nordisk Investigational Site Pembroke Pines Florida 33028
Novo Nordisk Investigational Site Conyers Georgia 30094-5965
Novo Nordisk Investigational Site New Orleans Louisiana 70121
Novo Nordisk Investigational Site Rockville Maryland 20852
Novo Nordisk Investigational Site Boston Massachusetts 02118
Novo Nordisk Investigational Site Kalamazoo Michigan 49009
Novo Nordisk Investigational Site Omaha Nebraska 68144
Novo Nordisk Investigational Site Henderson Nevada 89052
Novo Nordisk Investigational Site Las Vegas Nevada 89120
Novo Nordisk Investigational Site Brooklyn New York 11229
Novo Nordisk Investigational Site Asheboro North Carolina 27203
Novo Nordisk Investigational Site Cincinnati Ohio 45242
Novo Nordisk Investigational Site Oklahoma City Oklahoma 73104
Novo Nordisk Investigational Site Downingtown Pennsylvania 19335-2620
Novo Nordisk Investigational Site Reading Pennsylvania 19609
Novo Nordisk Investigational Site Greenville South Carolina 29605-4254
Novo Nordisk Investigational Site Greer South Carolina 29651
Novo Nordisk Investigational Site Memphis Tennessee 38119-3821
Novo Nordisk Investigational Site Fort Worth Texas 76132
Novo Nordisk Investigational Site Houston Texas 77025-1669
Novo Nordisk Investigational Site San Antonio Texas 78229
Novo Nordisk Investigational Site Sugar Land Texas 77478
Novo Nordisk Investigational Site Ogden Utah 84405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01850615, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 11, 2019 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01850615 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →